Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
Gemini Therapeutics (Nasdaq: GMTX) has announced that its CEO, Jason Meyeburg, will present virtually at the H.C. Wainwright Ophthalmology Conference on August 17 at 9:00 AM ET. The event will be accessible via a live webcast on the company's website, with a replay available for 30 days post-event.
The company focuses on precision medicine for age-related macular degeneration (AMD). Its lead candidate, GEM103, aims to restore retinal health and is undergoing Phase 2a trials.
- None.
- None.
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 9:00 AM ET.
A live webcast of the event will be available on the "Events & Presentations" page on the Company's website. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. Gemini has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.
For more information, visit www.geminitherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005122/en/
FAQ
What is the date and time of the Gemini Therapeutics presentation?
Where can I watch the Gemini Therapeutics conference presentation?
What is GEM103 and its significance in AMD treatment?
How long will the Gemini Therapeutics conference replay be available?
